JSJoint Symposium
ASAsian Hematology Symposium
SSScientific Session
LSLuncheon Symposium
ESEducation Session (This sessions will be provided with simultaneous interpretation in Korean.)
| Time | VISTA 1 | VISTA 2 | VISTA 3 | Grand Hall |
|---|---|---|---|---|
| 08:00-09:00 | Registration | |||
| 09:00 | Opening Remarks | |||
| 09:00 - 10:30 | [JS01] KAI-KSH Joint Symposium - Immunotherapeutics in Blood Disease |
[SS01] Bone Marrow Failure | ||
|
IL-7-hyFc, a long-acting recombinant IL-7 protein, generates anti-tumor activity by modulating both adaptive and innate immune cells in the tumor microenvironment (Seung-Woo Lee, Korea) Towards next-generation CAR-T cell therapy for cancer  (Chan Hyuk Kim, Korea) Immunotherapeutics in blood disease: Cytotoxic T lymphocyte therapy (Hyewon Lee, Korea) Immune checkpoint inhibitor in lymphoma (Yoon Seok Choi, Korea) |
Paroxysmal nocturnal hemoglobinuria in bone marrow failure (Jun Ho Jang, Korea) Germline mutations in inherited bone marrow failure (Jean Soulier, France) Telomere length and somatic mutations in aplastic anemia (Dong Soon Lee, Korea) |
|||
| 10:30 - 10:45 | Coffee Break | |||
| 10:45- 11:45 | Plenary Lecture I - Gene Therapy in Hematology | |||
|
Application of CRISPR/Cas-9 in blood disease (Matthew H. Porteus, USA) Gene therapy for hemophilia-will there be a new era in hemophilia treatment? (Katherine Ann High, USA) |
||||
| 11:45- 12:45 | Presidential Symposium | |||
|
Stem cells in human AML (Ravi Majeti, USA) Precision medicine in pediatric acute lymphoblastic leukemia (Ching-Hon Pui, USA) |
||||
| 12:45 - 13:40 | [LS01] Novartis | [LS02] Amgen | [LS03] Roche | |
|
Treatment free remission in CML: Promise and challenges (Adam Mead, UK) |
Optimal treatment sequencing for patients with relapsed/refractory multiple myeloma (Ajai Chari, USA) |
Current issues in the treatment of B-cell lymphoma (Seok Jin Kim, Korea) |
||
| 13:40 - 14:40 | [AS01] Asian Hematology Symposium I: Lymphoid | [AS02] Asian Hematology Symposium II: Myeloid | ||
|
Treatment of Philadelphia chromosome positive acute lymphoblastic leukemia- Korean perspectives (Young Rok Do, Korea) Hematopoietic stem cell transplantation for adult acute lymphoblastic Leukemia in Taiwan – On Behalf of TSBMT (Tran-Der Tan, Taiwan) Adult ALL in Malaysia (Sen Mui Tan, Malaysia) |
CML in Philippines (Priscilla B. Caguioa, Philippines) Outcome of allogeneic hematopoietic stem cell transplantation for SAA and PNH at Vietnam national institute of haematology and blood transfusion (Binh Thi Thanh Vo, Vietnam) Hemoglobinopathy in Thailand (Duantida Songdej, Thailand) |
|||
| 14:40 - 14:55 | Coffee Break | |||
| 14:55 - 16:25 | [JS02] KOGO-KSH Joint Symposium - Genomics for Precision Hematology | [SS02] Multiple Myeloma: How is MM Developed and Progressed? From 3 Different Viewpoint | [SS03] Transplantation/Cell Therapy | [ES01] Iron Metabolism |
|
Understanding angioimmunoblastic T-cell lymphoma: from genomics to animal pathology (Jaesang Kim, Korea) Genomic pathogenesis of epstein–barr virus (EBV)- induced diffuse large B cell lymphoma (Sung-Yup Cho, Korea) Current status of precision hematology (Young-Uk Cho, Korea) Clinical application of personalized medicine for AML (Joon-Ho Moon, Korea) |
Immunological weapons against multiple myeloma (Je-Jung Lee, Korea) Roles of bone marrow microenvironment in clonal evolution and drug resistance of multiple myeloma (Yusuke Furukawa, Japan) Antigen-mediated regulation in Myeloma (Madhav V. Dhodapkar, USA) |
TK cell therapy (Maria Chiara Bonini, Italy) Updates on CAR T cell therapy for multiple myeloma (Jesús G. Berdeja, USA) Accelerating personalization of immune therapies for blood cancers (Larry W. Kwak, USA) |
Iron metabolism in hemoglobinopathies (Vip Viprakasit, Thailand) Deferasirox for iron overload patients: Preserving organ functions (Norbert Gattermann, Germany) Management of iron overload in MDS (Heather Alice Leitch, Canada) |
|
| 16:25 - 16:40 | Break | |||
| 16:40 - 18:10 | [SS04] Myeloproliferative Neoplasm | [SS05] Bleeding Disorder/Thrombosis | [SS06] Pediatric Disease | [ES02] Indolent Lymphoma |
|
Genetic causes of myeloproliferative diseases: Stratification of patients and new therapeutic targets (Robert Kralovics, Austria) Molecular mechanism of MPN development by mutant calreticulin (Norio Komatsu, Japan) Interferon in myeloproliferative neoplasms (Jean-Jacques Kiladjian, France) |
Progress in gene therapy for hemophilia A and B (Glenn F. Pierce, USA) Individualized treatment for hemophilia : population pharmacokinetics approach (Cindy H. T. Yeung, Canada) Mechanisms of cancer-associated thrombosis (Nigel Mackman, USA) |
Inherited hematologic malignancies (Lucy Ann Godley, USA) GATA2 deficiency:How to make the diagnosis? how to treat it? (Jean Donadieu, France) Roles of monosomy 7 and SAMD9/SAMD9L mutations in myeloid leukemogenesis (Hirotaka Matsui, Japan) |
Mantle cell lymphoma -from the clinic to genetics (Mats Jerkeman, Sweden) From genetics to the clinic: Follicular lymphoma (Gilles Salles, France) From genetics to the clinic of chronic lymphocytic leukemia (Wei Xu, China) |
|
| 18:10 - 18:30 | Break | |||
| 18:30 - 20:00 | Welcome Reception | |||